Diffuse midline glioma is one of the most difficult pediatric cancers to treat. This study investigated the feasibility of 13C magnetic resonance metabolic imaging of hyperpolarized [1-13C]pyruvate for monitoring response to novel therapies in diffuse midline glioma. Treatment with panobinostat was associated with a reduction in hyperpolarized lactate and a reduced LDHA activity in an in vitro experiment. Radiotherapy led to a reduction in the ratio of lactate to pyruvate in rats bearing diffuse midline glioma. The results suggest that hyperpolarized 13C metabolic imaging may provide an early noninvasive biomarker to monitor therapy response in diffuse midline glioma.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords